1. Home
  2. RANI vs RLYB Comparison

RANI vs RLYB Comparison

Compare RANI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RANI
  • RLYB
  • Stock Information
  • Founded
  • RANI 2012
  • RLYB 2018
  • Country
  • RANI United States
  • RLYB United States
  • Employees
  • RANI N/A
  • RLYB N/A
  • Industry
  • RANI Medicinal Chemicals and Botanical Products
  • RLYB Biotechnology: Pharmaceutical Preparations
  • Sector
  • RANI Health Care
  • RLYB Health Care
  • Exchange
  • RANI Nasdaq
  • RLYB Nasdaq
  • Market Cap
  • RANI 24.2M
  • RLYB 24.1M
  • IPO Year
  • RANI 2021
  • RLYB 2021
  • Fundamental
  • Price
  • RANI $0.49
  • RLYB $0.58
  • Analyst Decision
  • RANI Strong Buy
  • RLYB Hold
  • Analyst Count
  • RANI 4
  • RLYB 2
  • Target Price
  • RANI $7.75
  • RLYB N/A
  • AVG Volume (30 Days)
  • RANI 274.5K
  • RLYB 308.6K
  • Earning Date
  • RANI 11-13-2025
  • RLYB 11-06-2025
  • Dividend Yield
  • RANI N/A
  • RLYB N/A
  • EPS Growth
  • RANI N/A
  • RLYB N/A
  • EPS
  • RANI N/A
  • RLYB N/A
  • Revenue
  • RANI $1,200,000.00
  • RLYB $761,000.00
  • Revenue This Year
  • RANI N/A
  • RLYB N/A
  • Revenue Next Year
  • RANI N/A
  • RLYB N/A
  • P/E Ratio
  • RANI N/A
  • RLYB N/A
  • Revenue Growth
  • RANI N/A
  • RLYB 154.51
  • 52 Week Low
  • RANI $0.39
  • RLYB $0.22
  • 52 Week High
  • RANI $3.75
  • RLYB $1.24
  • Technical
  • Relative Strength Index (RSI)
  • RANI 48.32
  • RLYB 50.68
  • Support Level
  • RANI $0.49
  • RLYB $0.48
  • Resistance Level
  • RANI $0.53
  • RLYB $0.60
  • Average True Range (ATR)
  • RANI 0.03
  • RLYB 0.04
  • MACD
  • RANI 0.00
  • RLYB -0.00
  • Stochastic Oscillator
  • RANI 45.43
  • RLYB 49.55

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Share on Social Networks: